Repeat Dosing of Psilocybin in Migraine Headache
Brief Summary
In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured.
Condition or Disease
- Migraine Headache
Phase
Study Design
Study type: | Interventional |
---|---|
Status: | Recruiting |
Study results: | No Results Available |
Age: | 21 Years to 65 Years (Adult, Older Adult) |
Enrollment: | 24 () |
Funded by: | Other |
Masking |
Clinical Trial Dates
Start date: | Aug 10, 2021 | |
---|---|---|
Primary Completion: | Jul 15, 2022 | |
Completion Date: | Jul 15, 2023 | |
Study First Posted: | Jan 06, 2020 | |
Results First Posted: | Aug 30, 2020 | |
Last Updated: | Oct 25, 2021 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Migraine headache is a common medical condition and a top cause of disability worldwide. Treatment options for migraine headache are many and varied, though an approximated 10% of migraineurs is refractory to medication and thus, there is a need to develop alternative treatments. There is anecdotal evidence supporting lasting therapeutic effects after limited dosing of psilocybin and related compounds in headache disorders. The cause of this unique effect remains unknown, though the drug class has demonstrable anti-inflammatory activity, a biological process relevant to migraine and other headache disorders. In seeking to understand the capacity for psilocybin to reduce migraine headache burden, this study will investigate single and repeated dosing of psilocybin up to two doses. In seeking to identify an underlying mechanism in psilocybin's effects, neuroinflammatory markers for migraine headache will be measured. The results from this study will serve in the development of larger investigations seeking to understand the effects of psilocybin and related compounds in headache disorders.
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 21 |
Maximum Age: | 65 |
This clinical trial is recruiting
Are you interested in participating in this trial or others? We'd love to help.
More Details
NCT Number: | NCT04218539 |
---|---|
Other IDs: | 2000026974 |
Study URL: | https://ClinicalTrials.gov/show/NCT04218539 |
Last updated: Jun 16, 2022